Peptides May Soon Be Legal. These Companies Are Ready To Cash In
With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.
Amy Feldman, Forbes Staff
Forbes
2 min read
6/10
Key Takeaways
An FDA advisory panel is expected this week to recommend legal production of up to seven peptides, including BPC-157 and semax.
Legalization could create a $1–2 billion U.S. market within three years, driven by compounding pharmacies and telehealth platforms.
Telehealth companies like Hims & Hers and Ro are positioning to become primary distributors, already building patient pipelines.
Compounding pharmacies are investing in sterile manufacturing capacity and custom dose formulations to capture the new market.
Critics cite insufficient long-term safety data, particularly for peptides used by athletes for performance and recovery.
A forthcoming FDA panel recommendation could legalize the production of up to seven peptides, igniting a gold rush among compounding pharmacies and telehealth companies. The panel is expected to advise the agency this week that certain peptides—short chains of amino acids used for everything from muscle growth to anti-aging—can be legally manufactured and sold, marking a seismic shift in the $4 billion U.S. peptide market. Today, most peptides are either imported from unregulated overseas labs or obtained through gray-market sources, exposing consumers to quality and safety risks. The potential legalization would allow licensed compounding pharmacies to produce standard approved peptides, while telehealth platforms like Hims & Hers and Ro are already building patient pipelines and fulfillment networks. If the FDA adopts the panel's recommendation—which typically happens within months—patients could access peptide therapies through telemedicine consultations and local compounding pharmacies, slashing costs and wait times compared to current underground supply chains. The move comes amid a broader FDA push to modernize regulation of "outsider" drug categories, including medical cannabis and certain lab-made hormones. Proponents argue that legal peptide production will improve quality control, reduce counterfeit risks, and expand patient access to treatments for metabolic disorders, recovery, and longevity. Critics, however, warn of potential overuse and insufficient long-term safety data, especially for peptides popular among athletes and biohackers. For companies, the prize is enormous: a legal U.S. market for peptides could be worth $1–2 billion within three years, with telehealth platforms capturing a large share of the distribution. Compounding pharmacies, which can customize doses and combinations, are investing in sterile manufacturing capacity. Investors are circling: startups like Fountain Health and agenus have seen their valuations rise on the news. The FDA panel, the schedules for which were announced last month, is expected to vote on individual peptides including BPC-157 (used for gut health and tissue repair) and semax (a nootropic). The decision will likely set a precedent for other gray-market substances, potentially reshaping the broader wellness and performance-enhancement industries. Observers believe that, if approved, legal peptide production could begin within six months, once the FDA issues formal guidance and pharmacies obtain necessary compounding permits. The next milestone to watch is the panel's vote expected this Friday, followed by a 90-day public comment period before the FDA's final ruling. For now, telehealth companies are already onboarding new patients, ready to prescribe peptides the moment the legal door opens.
Frequently Asked Questions
Peptides are short chains of amino acids that act as signaling molecules in the body. They are used for a variety of therapeutic purposes, including tissue repair, muscle growth, anti-aging, and cognitive enhancement. Currently, most peptides are obtained from unregulated overseas sources.
The FDA is responding to growing demand for safer, regulated access to peptides. An advisory panel is expected to recommend legal production of up to seven peptides, citing quality control, safety, and patient access as key drivers. The move follows years of gray-market imports and compounding pharmacy requests.
If the FDA adopts the panel's recommendation, patients could obtain peptides through a telehealth consultation with a licensed provider. The prescription would be filled by a compounding pharmacy, which can prepare custom doses. Legal distribution is expected to start within six months of the final FDA ruling.
Telehealth platforms like Hims & Hers and Ro are likely to benefit, as they can integrate peptide prescriptions into their existing models. Compounding pharmacies such as CAPS and Olympia Pharmacy are investing in sterile manufacturing. Startups focused on longevity and performance are also positioning for the market.
Safety depends on the specific peptide and its use. Proponents argue that regulated production improves purity and dosing accuracy. However, critics note limited long-term studies for many peptides, especially those used by athletes for performance. The FDA's approval process will require evidence of safety and efficacy for each peptide.
The FDA panel vote is expected this Friday. After the recommendation, the FDA will open a 90-day public comment period before issuing a final ruling. If approved, legal production could begin within three to six months, pending pharmacy compounding permits and FDA guidance.
